Advanced search

Vol 27, No 1 (2022)
Review paper
Published online: 2021-12-10

open access

View PDF Download PDF file
Page views 5749
Article views/downloads 1052
Get Citation

Connect on Social Media

Connect on Social Media

Stereotactic radiotherapy for liver oligometastases

Claudia Menichelli1, Franco Casamassima2, Cynthia Aristei3, Gianluca Ingrosso3, Simona Borghesi4, Fabio Arcidiacono5, Valentina Lancellotta6, Ciro Franzese7, Stefano Arcangeli8
DOI: 10.5603/RPOR.a2021.0130
Rep Pract Oncol Radiother 2022;27(1):32-39.

Abstract

The liver is the first metastatic site in 15–25% of colorectal cancer patients and one of the first metastatic sites for lung and breast cancer patients.

A computed tomography (CT) scan with contrast medium is a standard procedure for assessing liver lesions but magnetic resonance imaging (MRI) characterizes small lesions better thanks to its high soft-tissue contrast. Positron emission tomography with computed tomography (PET-CT) plays a complementary role in the diagnosis of liver metastases. Triphasic (arterial, venous and time-delayed) acquisition of contrast-medium CT images is the first step in treatment planning. Since the liver exhibits a relatively wide mobility due to respiratory movements and bowel filling, appropriate techniques are needed for target identification and motion management. Contouring requires precise recognition of target lesion edges. Information from contrast MRI and/or PET-CT is crucial as they best visualize metastatic disease in the parenchyma. Even though different fractionation schedules were reported, doses and fractionation schedules for liver stereotactic radiotherapy (SRT) have not yet been established. The best local control rates were obtained with BED10 values over 100 Gy. Local control rates from most retrospective studies, which were limited by short follow-ups and included different primary tumors with intrinsic heterogeneity, ranged from 60% to 90% at 1 and 2 years. The most common SRT-related toxicities are increases in liver enzymes, hyperbilirubinemia and hypoalbuminemia. Overall, late toxicity is mild even in long-term follow-ups. 

Keywords: stereotactic radiotherapyradiosurgeryoligometastasisliver metastasesorgan motionhypofractionationbedlocal controltoxicity

Article available in PDF format

View PDF Download PDF file

References

  1. Sheth KR, Clary BM. Management of hepatic metastases from colorectal cancer. Clin Colon Rectal Surg. 2005; 18(3): 215–223.
    CrossRefPubMed
  2. Jegatheeswaran S, Mason JM, Hancock HC, et al. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg. 2013; 148(4): 385–391.
    CrossRefPubMed
  3. Turdean S, Gurzu S, Turcu M, et al. Liver metastases: incidence and clinicopathological data. Acta Medica Marisiensis. 2012; 58: 254–258.
  4. Görög D, Tóth A, Weltner J. Prognosis of untreated liver metastasis from rectal cancer. Acta Chir Hung. 1997; 36(1-4): 106–107.
    PubMed
  5. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006; 244(2): 254–259.
    CrossRefPubMed
  6. Hoe AL, Royle GT, Taylor I. Breast liver metastases--incidence, diagnosis and outcome. J R Soc Med. 1991; 84(12): 714–716.
    PubMed
  7. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005; 241(5): 715–22, discussion 722.
    CrossRefPubMed
  8. Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006; 13(5): 668–676.
    CrossRefPubMed
  9. Ellis OV, Hornock SL, Bohan PM, et al. Impact of Hepatic Metastasectomy in the Multimodal Treatment of Metastatic Breast Cancer. J Surg Res. 2021 [Epub ahead of print]; 268: 650–659.
    CrossRefPubMed
  10. Kim M, Son S, Won Y, et al. Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver. BioMed Res Int. 2014; 2014: 1–9.
    CrossRefPubMed
  11. Loi M, Desideri I, Dominici L, et al. Thermal Ablation versus SBRT in liver tumours: pros and cons. Med Oncol. 2020; 37(6): 52.
    CrossRefPubMed
  12. Correa RJM, Salama JK, Milano MT, et al. Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management. Cancer J. 2016; 22(4): 247–256.
    CrossRefPubMed
  13. Nieuwenhuizen S, Puijk RS, van den Bemd B, et al. Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group. Cancers (Basel). 2020; 12(7).
    CrossRefPubMed
  14. Wernecke K, Rummeny E, Bongartz G, et al. Detection of hepatic masses in patients with carcinoma: comparative sensitivities of sonography, CT, and MR imaging. AJR Am J Roentgenol. 1991; 157(4): 731–739.
    CrossRefPubMed
  15. Larsen LP, Rosenkilde M, Christensen H, et al. The value of contrast enhanced ultrasonography in detection of liver metastases from colorectal cancer: a prospective double-blinded study. Eur J Radiol. 2007; 62(2): 302–307.
    CrossRefPubMed
  16. Quaia E, D'Onofrio M, Palumbo A, et al. Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol. 2006; 16(7): 1599–1609.
    CrossRefPubMed
  17. Robinson PJ. The early detection of liver metastases. Cancer Imag. 2002; 2: 1–3.
  18. Kulemann V, Schima W, Tamandl D, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol. 2011; 79(2): e1–e6.
    CrossRefPubMed
  19. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005; 237(1): 89–98.
    CrossRefPubMed
  20. Ruers TJM, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002; 20(2): 388–395.
    CrossRefPubMed
  21. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004; 240(3): 438–47; discussion 447.
    CrossRefPubMed
  22. Dagan R, Lo SS, Redmond KJ, et al. A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up. Acta Oncol. 2016; 55(5): 633–637.
    CrossRefPubMed
  23. John R, Ho F, Appalanaido G, et al. Can radiotherapy finally “go live” in the management of liver metastases? Hepatoma Res. 2020.
    CrossRef
  24. Schefter TE, Kavanagh BD. Radiation therapy for liver metastases. Semin Radiat Oncol. 2011; 21(4): 264–270.
    CrossRefPubMed
  25. Palacios-Eito A, García-Cabezas S. Oligometastatic disease, the curative challenge in radiation oncology. World J Clin Oncol. 2015; 6(4): 30–34.
    CrossRefPubMed
  26. Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012; 82(3): 1047–1057.
    CrossRefPubMed
  27. Franzese C, Comito T, Viganò L, et al. Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. Clin Breast Cancer. 2020; 20(6): 480–486.
    CrossRefPubMed
  28. Romesser PB, Neal BP, Crane CH. External Beam Radiation Therapy for Liver Metastases. Surg Oncol Clin N Am. 2021; 30(1): 159–173.
    CrossRefPubMed
  29. Riou O, Llacer Moscardo C, Fenoglietto P, et al. SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques. Rep Pract Oncol Radiother. 2017; 22(2): 103–110.
    CrossRefPubMed
  30. Kowalchuk RO, Waters MR, Richardson KM, et al. A single-institutional experience with low dose stereotactic body radiation therapy for liver metastases. Rep Pract Oncol Radiother. 2020; 25(6): 987–993.
    CrossRefPubMed
  31. Ohri N, Tomé WA, Méndez Romero A, et al. Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys. 2021; 110(1): 188–195.
    CrossRefPubMed
  32. Kok END, Jansen EPM, Heeres BC, et al. High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases. Clin Transl Radiat Oncol. 2020; 20: 45–50.
    CrossRefPubMed
  33. Joo JiH, Park JH, Kim JC, et al. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. Int J Radiat Oncol Biol Phys. 2017; 99(4): 876–883.
    CrossRefPubMed
  34. Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011; 117(17): 4060–4069.
    CrossRefPubMed
  35. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27(10): 1572–1578.
    CrossRefPubMed
  36. Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013; 86(2): 336–342.
    CrossRefPubMed
  37. Folkert MR, Meyer JJ, Aguilera TA, et al. Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases. Int J Radiat Oncol Biol Phys. 2021; 109(5): 1387–1395.
    CrossRefPubMed
  38. Klement RJ, Abbasi-Senger N, Adebahr S, et al. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer. 2019; 19(1): 173.
    CrossRefPubMed
  39. Ahmed KA, Caudell JJ, El-Haddad G, et al. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016; 95(5): 1399–1404.
    CrossRefPubMed
  40. Klement RJ, Guckenberger M, Alheid H, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017; 123(2): 227–233.
    CrossRefPubMed
  41. Andratschke N, Alheid H, Allgäuer M, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018; 18(1): 283.
    CrossRefPubMed
  42. Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol. 2006; 45(7): 831–837.
    CrossRefPubMed
  43. Comito T, Clerici E, Tozzi A, et al. Liver metastases and SBRT: A new paradigm? Rep Pract Oncol Radiother. 2015; 20(6): 464–471.
    CrossRefPubMed
  44. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010; 37(8): 4078–4101.
    CrossRefPubMed
  45. Kothary N, Heit JJ, Louie JD, et al. Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy. J Vasc Interv Radiol. 2009; 20(2): 235–239.
    CrossRefPubMed
  46. Stick LB, Vogelius IR, Risum S, et al. Intrafractional fiducial marker position variations in stereotactic liver radiotherapy during voluntary deep inspiration breath-hold. Br J Radiol. 2020; 93(1116): 20200859.
    CrossRefPubMed
  47. Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future. Lancet Oncol. 2020; 21(2): e74–e82.
    CrossRefPubMed
  48. Gani C, Boeke S, McNair H, et al. Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac - Feasibility, workflow data and patient acceptance. Clin Transl Radiat Oncol. 2021; 26: 55–61.
    CrossRefPubMed
  49. Hall WA, Straza MW, Chen X, et al. Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac. PLoS One. 2020; 15(8): e0236570.
    CrossRefPubMed
  50. Rubio C, Hernando-Requejo O, Zucca Aparicio D, et al. Image guided SBRT for multiple liver metastases with ExacTrac Adaptive Gating. Rep Pract Oncol Radiother. 2017; 22(2): 150–157.
    CrossRefPubMed
  51. Jarraya H, Mirabel X, Taieb S, et al. Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking. Radiat Oncol. 2013; 8: 24.
    CrossRefPubMed
  52. Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012; 82(3): 1047–1057.
    CrossRefPubMed
  53. Lee J, Shin IS, Yoon WS, et al. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol. 2020; 145: 63–70.
    CrossRefPubMed
  54. Scorsetti M, Comito T, Clerici E, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol. 2018; 13(1): 234.
    CrossRefPubMed
  55. Menichelli C, Casamassima F, Panichi M, et al. SBRT for Liver Metastases: Results on 173 Treated Lesions. Int J Radiat Oncol Biol Phys. 2012; 84(3): S191.
    CrossRef
  56. Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006; 45(7): 838–847.
    CrossRefPubMed
  57. Lanciano R, Lamond J, Yang J, et al. Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol. 2012; 2: 23.
    CrossRefPubMed
  58. Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol. 2010; 33(2): 157–163.
    CrossRefPubMed
  59. Cacciola A, Parisi S, Tamburella C, et al. Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when? Rep Pract Oncol Radiother. 2020; 25(3): 299–306.
    CrossRefPubMed
  60. Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015; 5(5): e443–e449.
    CrossRefPubMed
  61. Bae SH, Kim MS, Jang WIl, et al. Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions. J Korean Med Sci. 2015; 30(8): 1055–1061.
    CrossRefPubMed
  62. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006; 45(7): 823–830.
    CrossRefPubMed
  63. Kim M, Son SH, Won YK, et al. Stereotactic ablative radiotherapy for oligometastatic disease in liver. Biomed Res Int. 2014; 2014: 340478.
    CrossRefPubMed
  64. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009; 27(10): 1585–1591.
    CrossRefPubMed
  65. Katz AW, Carey-Sampson M, Muhs AG, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007; 67(3): 793–798.
    CrossRefPubMed
  66. Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys. 2011; 81(3): e39–e47.
    CrossRefPubMed
  67. Habermehl D, Herfarth KK, Bermejo JL, et al. Single-dose radiosurgical treatment for hepatic metastases--therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol. 2013; 8: 175.
    CrossRefPubMed
  68. Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011; 18(4): 1081–1087.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note